Skip to main content
. 2022 May 23;7(10):e158856. doi: 10.1172/jci.insight.158856

Figure 1. EPO synergizes with CTLA4-Ig to prolong heart transplant survival through ligation of EPOR expressed on myeloid cells.

Figure 1

(A) Schematic of design and treatment regimen. (B) Survival of BALB/c hearts transplanted into WT B6 recipients and either not treated (n = 3) or treated with EPO alone (n = 3), CTLA4-Ig alone (n = 4), or EPO+CTLA4-Ig (n = 5). Results compared among groups by Kaplan-Meier (log-rank) survival analysis. (C) Representative flow cytometry plots of intracellular pSTAT5 in splenic myeloid or nonmyeloid cells obtained from EPORfl/fl or EPORfl/fl LysM-Cre animals 30 minutes after in vitro treatment with vehicle or EPO as indicated. (D) Quantified results (n = 3/group) of pSTAT5 in splenic myeloid cells isolated from EPORfl/fl or EPORfl/fl LysM-Cre animals 30 minutes after in vitro treatment with vehicle or EPO. Statistics in D compared by 2-tailed Student’s t test. Representative of 2 independent experiments. (E) Survival of BALB/c hearts transplanted into B6 EPORfl/fl, EPORfl/fl LysM-Cre, or EPORfl/fl CD4-Cre recipients and treated with or without CTLA4-Ig and with or without EPO as indicated. Results compared among groups by Kaplan-Meier (log-rank) survival analysis. n = 6 per group except for untreated EPORfl/fl and EPORfl/fl LysM-Cre (n = 3/group). *P < 0.05; ***P < 0.001; NS, not significant.